{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:30:05Z","timestamp":1790188205274,"version":"4.1.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>At diagnosis, the majority of patients with intrahepatic cholangiocarcinoma (IHCC) present with advanced disease and a poor prognosis. Comprehensive genomic profiling (CGP) early in the disease course may increase access to targeted therapies and clinical trials; however, unresolved issues remain surrounding the optimal biopsy type to submit for CGP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Mutational frequencies between primary tumor biopsies (Pbx), metastatic biopsies (Mbx), and liquid biopsies (Lbx) in 1,632 patients with IHCC were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Potentially actionable alterations were found in 52%, 34%, and 35% of patients in the Pbx, Mbx, and Lbx cohorts, respectively. In Pbx, Mbx, and Lbx, FGFR2 rearrangements were found in 9%, 6%, and 4%, and IDH1 mutations were identified in 16%, 5%, and 9% patients, respectively. Moreover, alterations in FGFR2 and IDH1 were significantly associated with distinct ancestries, including 2.1-fold enrichment for FGFR2 rearrangements in patients with African ancestry and 1.5-fold enrichment for IDH1 mutations in patients with admixed American (Hispanic) ancestry. Finally, the publication of biomarker-driven clinical trials in IHCC correlated with changing CGP testing patterns. Significant correlations between patient characteristics and IHCC trial disclosures were observed, including a significant decrease from time between biopsy and CGP testing, and more frequent testing of primary versus metastatic samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Overall, because of the high likelihood of identifying actionable genomic alterations, CGP should be considered for the majority of patients with inoperable IHCC, and Lbx and Mbx can be considered as part of the diagnostic suite.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for Practice<\/jats:title><jats:p>Comprehensive genomic profiling (CGP) should be considered for all patients with intrahepatic cholangiocarcinoma (IHCC) or suspected IHCC, as actionable alterations were commonly found in multiple genes and a wide variety of FGFR2 fusion partners were identified. The disclosure of IHCC trial data correlated with increased use of CGP, an encouraging trend that moves new therapeutic options forward for rare cancers with a rare biomarker. Although tissue from the primary lesion may identify actionable alterations at higher rates, CGP of a liquid biopsy or metastatic site can be considered, particularly if the primary tissue block is exhausted.<\/jats:p><\/jats:sec>","DOI":"10.1002\/onco.13844","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T11:28:58Z","timestamp":1622719738000},"page":"787-796","source":"Crossref","is-referenced-by-count":46,"title":["Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns"],"prefix":"10.1093","volume":"26","author":[{"given":"Mason A.","family":"Israel","sequence":"first","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Danziger","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"McGregor","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthikeyan","family":"Murugesan","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Gjoerup","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Sokol","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Tukachinsky","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California, San Diego Moores Cancer Center, La Jolla, California, USA"},{"name":"Department of Medicine, Division of Hematology and Oncology, University of California, San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California, San Diego Moores Cancer Center, La Jolla, California, USA"},{"name":"Department of Medicine, Division of Hematology and Oncology, University of California, San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Sicklick","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California, San Diego Moores Cancer Center, La Jolla, California, USA"},{"name":"Department of Surgery, Division of Surgical Oncology, University of California, San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halla S.","family":"Nimeiri","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R.","family":"Oxnard","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, Massachusetts, USA"},{"name":"Departments of Urology and Pathology, SUNY Upstate Medical University, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"2022012102313811200_onco13844-bib-0001","doi-asserted-by":"crossref","first-page":"789","DOI":"10.21037\/jgo.2016.08.12","article-title":"The rise of the FGFR inhibitor in advanced biliary cancer: The next cover of time magazine?","volume":"7","author":"Rizvi","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"2022012102313811200_onco13844-bib-0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/1477-3163.151940","article-title":"Cancer review: Cholangiocarcinoma","volume":"14","author":"Ghouri","year":"2015","journal-title":"J Carcinog"},{"key":"2022012102313811200_onco13844-bib-0003","doi-asserted-by":"crossref","first-page":"370","DOI":"10.6004\/jnccn.2017.7056","article-title":"Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States","volume":"16","author":"Mukkamalla","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2022012102313811200_onco13844-bib-0004","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10555-016-9602-8","article-title":"Genomics of gallbladder cancer: The case for biomarker-driven clinical trial design","volume":"35","author":"Sicklick","year":"2016","journal-title":"Cancer Metastasis Rev"},{"key":"2022012102313811200_onco13844-bib-0005","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"2022012102313811200_onco13844-bib-0006","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jvir.2013.03.019","article-title":"Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma","volume":"24","author":"Ray","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"2022012102313811200_onco13844-bib-0007","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2022012102313811200_onco13844-bib-0008","doi-asserted-by":"crossref","first-page":"101165","DOI":"10.18632\/oncotarget.20932","article-title":"Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC\/UICC TNM staging system","volume":"8","author":"Meng","year":"2017","journal-title":"Oncotarget"},{"issue":"15","key":"2022012102313811200_onco13844-bib-0009","article-title":"Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH)","volume":"37","author":"Javle","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"2022012102313811200_onco13844-bib-0010","article-title":"Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma","volume":"37","author":"Silverman","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022012102313811200_onco13844-bib-0011","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat Commun"},{"key":"2022012102313811200_onco13844-bib-0012","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"The Oncologist"},{"key":"2022012102313811200_onco13844-bib-0013","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2022012102313811200_onco13844-bib-0014","doi-asserted-by":"crossref","DOI":"10.1177\/1073274817729241","article-title":"Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma","volume":"24","author":"Chun","year":"2017","journal-title":"Cancer Control"},{"key":"2022012102313811200_onco13844-bib-0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"2022012102313811200_onco13844-bib-0016","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: Utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"suppl 5","key":"2022012102313811200_onco13844-bib-0017","doi-asserted-by":"crossref","first-page":"v279","DOI":"10.1093\/annonc\/mdz247.053","article-title":"FGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA)","volume":"30","author":"Almquist","year":"2019","journal-title":"Ann Oncol"},{"key":"2022012102313811200_onco13844-bib-0018","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"issue":"suppl 15","key":"2022012102313811200_onco13844-bib-0019","article-title":"The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA)","volume":"38","author":"Goyal","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022012102313811200_onco13844-bib-0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: A unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2022012102313811200_onco13844-bib-0021","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"2022012102313811200_onco13844-bib-0022","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: First approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"suppl 5","key":"2022012102313811200_onco13844-bib-0023","doi-asserted-by":"crossref","first-page":"v276","DOI":"10.1093\/annonc\/mdz247.047","article-title":"Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the fight-202 trial","volume":"30","author":"Hollebecque","year":"2019","journal-title":"Ann Oncol"},{"key":"2022012102313811200_onco13844-bib-0024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cytogfr.2019.12.005","article-title":"Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma","volume":"52","author":"Li","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"2022012102313811200_onco13844-bib-0025","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2022012102313811200_onco13844-bib-0026","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"2022012102313811200_onco13844-bib-0027","article-title":"Treating HER2-mutant advanced biliary tract cancer with neratinib: Benefits of HER2-directed targeted therapy in the phase 2 SUMMIT basket trial","volume":"30","author":"Harding","year":"2019","journal-title":"Ann Oncol"},{"key":"2022012102313811200_onco13844-bib-0028","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"2022012102313811200_onco13844-bib-0029","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion\u2013positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"2022012102313811200_onco13844-bib-0030","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh","year":"2019","journal-title":"Nat Med"},{"key":"2022012102313811200_onco13844-bib-0031","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1159\/000509075","article-title":"Favorable outcomes in FGFR fusion-positive cholangiocarcinomas and evolution on treatment noted on circulating tumor DNA liquid biopsies","volume":"13","author":"Kasi","year":"2020","journal-title":"Case Rep Oncol"},{"key":"2022012102313811200_onco13844-bib-0032","doi-asserted-by":"crossref","first-page":"13261","DOI":"10.1038\/s41598-019-49860-0","article-title":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","volume":"9","author":"Ettrich","year":"2019","journal-title":"Sci Rep"},{"key":"2022012102313811200_onco13844-bib-0033","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/ijc.33230","article-title":"Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers","volume":"148","author":"Okamura","year":"2021","journal-title":"Int J Cancer"},{"key":"2022012102313811200_onco13844-bib-0034","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2022012102313811200_onco13844-bib-0035","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jmoldx.2018.05.004","article-title":"Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA","volume":"20","author":"Clark","year":"2018","journal-title":"J Mol Diagn"},{"key":"2022012102313811200_onco13844-bib-0036","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2022012102313811200_onco13844-bib-0037","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability\u2013high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diag"},{"issue":"13","key":"2022012102313811200_onco13844-bib-0038","doi-asserted-by":"crossref","first-page":"1599a","DOI":"10.1158\/1538-7445.AM2019-1599","article-title":"Abstract 1599: Determining patient ancestry based on targeted tumor comprehensive genomic profiling","volume":"79","author":"Newberg","year":"2019","journal-title":"Cancer Res"},{"key":"2022012102313811200_onco13844-bib-0039","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2020.04.012","article-title":"Comprehensive analysis of genetic ancestry and its molecular correlates in cancer","volume":"37","author":"Carrot-Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"2022012102313811200_onco13844-bib-0040","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1101\/gr.094052.109","article-title":"Fast model-based estimation of ancestry in unrelated individuals","volume":"19","author":"Alexander","year":"2009","journal-title":"Genome Res"},{"key":"2022012102313811200_onco13844-bib-0041","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"2022012102313811200_onco13844-bib-0042","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2022012102313811200_onco13844-bib-0043","doi-asserted-by":"crossref","first-page":"v100","DOI":"10.1093\/annonc\/mdy149","article-title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors","volume":"29","author":"Meric-Bernstam","year":"2018","journal-title":"Ann Oncol"},{"issue":"8","key":"2022012102313811200_onco13844-bib-0044","article-title":"Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced\/metastatic or surgically unresectable cholangiocarcinoma (CCA) with\/without fibroblast growth factor (FGF)\/FGF receptor (FGFR) genetic alterations","volume":"29","author":"Hollebecque","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"2022012102313811200_onco13844-bib-0045","doi-asserted-by":"crossref","first-page":"187a","DOI":"10.1200\/JCO.2019.37.4_suppl.187","article-title":"Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E\u2013mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial","volume":"37","author":"Wainberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022012102313811200_onco13844-bib-0046","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"key":"2022012102313811200_onco13844-bib-0047","doi-asserted-by":"crossref","DOI":"10.21037\/hbsn.2019.AB065","article-title":"AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: Preliminary results","volume":"8","author":"Ng","year":"2019","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2022012102313811200_onco13844-bib-0048","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2022012102313811200_onco13844-bib-0049","article-title":"ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation","volume":"30","author":"Abou-Alfa","year":"2019","journal-title":"Ann Oncol"},{"key":"2022012102313811200_onco13844-bib-0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS One"},{"key":"2022012102313811200_onco13844-bib-0051","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"key":"2022012102313811200_onco13844-bib-0052","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jclinpath-2015-203394","article-title":"Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets","volume":"69","author":"Lee","year":"2016","journal-title":"J Clin Pathol"},{"key":"2022012102313811200_onco13844-bib-0053","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: A potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"2022012102313811200_onco13844-bib-0054","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: Subgroup analysis of a phase 2 nonrandomized clinical trial","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol"},{"key":"2022012102313811200_onco13844-bib-0055","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J Hepatol"},{"key":"2022012102313811200_onco13844-bib-0056","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1038\/ncomms7120","article-title":"Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity","volume":"6","author":"Fujimoto","year":"2015","journal-title":"Nat Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13844","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13844","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/9\/787\/42247153\/oncolo_26_9_787.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/9\/787\/42247153\/oncolo_26_9_787.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T04:24:57Z","timestamp":1725164697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/9\/787\/6512096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,6,18]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13844","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,6,18]]}}}